Physician profile
Manuela Conde
NPI 1538823075
$6,264.69
in general payments reported to CMS, 2019-2025
24 companies · $2,410 in 2025
The $2,410 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $675 · 2023: $912 · 2024: $2,090 · 2025: $2,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,313 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,312.80 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,052.28 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $556.54 | 2021-2025 | Winlevi |
| Arcutis Biotherapeutics, INC. | $552.57 | 2023-2025 | Zoryve |
| Genzyme Corporation | $432.69 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $411.14 | 2023-2025 | Sotyktu |
| Lilly USA, LLC | $408.72 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Incyte Corporation | $375.60 | 2023-2025 | Opzelura |
| Revance Therapeutics, INC. | $366.54 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $348.12 | 2022-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $335.54 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $289.06 | 2022-2025 | Libtayo, Dupixent |
| Leo Pharma INC. | $235.56 | 2022-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $197.91 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Allergan, INC. | $162.50 | 2022 | |
| Almirall LLC | $117.91 | 2024-2025 | Klisyri, Seysara |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.69 | 2024-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $98.04 | 2022-2023 | |
| Journey Medical Corporation | $71.38 | 2022-2025 | |
| Ucb, INC. | $37.51 | 2025 | Bimzelx |
| Pfizer INC. | $29.08 | 2025 | |
| Epi Health, LLC | $25.61 | 2022 | |
| Lnhc, INC | $24.37 | 2025 | Zelsuvmi |
| Si-Bone, INC. | $19.57 | 2024 | |
| Botanix Sb INC | $17.76 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuela Conde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.